Deals 2018/19 Archives

Alvotech and Kamada enter biosimilar commercialisation agreement

by Bioblast Editor | Dec 2, 2019 | Biosimilars Deals 2019

Alvotech and Kamada announce agreement to commercialise six biosimilar products in Israel. The first product is expected to be launched in Israel in 2022.

Alvotech and STADA enter commercialisation agreement for biosimilars in EU

by Bioblast Editor | Nov 6, 2019 | Biosimilars Deals 2019

Alvotech and STADA announce agreement for the commercialisation of seven biosimilars in all key European markets and selected markets outside Europe. Under the agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars,...

Biocon and Evotec enter strategic licensing agreement for biosimilar

by Bioblast Editor | Oct 14, 2019 | Biosimilars Deals 2019

Biocon and Evotec announce strategic licensing agreement for an early-stage biosimilar. Under this agreement, Biocon will take the asset through end-to-end development, IND filing, manufacturing and commercialisation and post-regulatory approval.

Biocon purchases R&D site from Pfizer

by Bioblast Editor | Sep 24, 2019 | Biosimilars Deals 2019

Biocon announces purchase of 60,000 square foot R&D site from Pfizer. The site in Chennai, India will house 250 scientists and is expected to be operational in a few months.

Alvotech and Prestige enter manufacturing partnership

by Bioblast Editor | Aug 27, 2019 | Biosimilars Deals 2019

Alvotech and Prestige announce manufacturing partnership, under which Alvotech will be responsible for commercial manufacturing of Prestige’s biosimilars.